---
schema_version: "secwatch.filing_event.v1"
accession: "0001645113-23-000039"
form_type: "8-K"
ticker: "NVCR"
cik: "0001645113"
company_name: "NovoCure Ltd"
filed_at: "2023-06-06T23:59:59+00:00"
generated_at: "2026-06-14T06:40:01.881449+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Novocure LUNAR phase 3 trial meets primary endpoint; median OS improved 3 months in NSCLC

## Summary
- LUNAR trial met primary endpoint: median OS 13.2 mo (TTFields+SOC) vs 9.9 mo (SOC alone); HR 0.74, p=0.035.
- ICI subgroup showed median OS 18.5 mo (TTFields+ICI) vs 10.8 mo (ICI alone); HR 0.63, p=0.03.
- TTFields therapy well-tolerated with no added systemic toxicities; few grade 3 device-related AEs.
- One-year survival 53% vs 42% (p=0.04); three-year survival 18% vs 7% (p=0.015).
- Novocure plans PMA submission to FDA in H2 2023 based on LUNAR data.

## SEC filing metadata
- accession: 0001645113-23-000039
- form_type: 8-K
- ticker: NVCR
- cik: 0001645113
- company_name: NovoCure Ltd
- filed_at: 2023-06-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645113/000164511323000039/0001645113-23-000039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645113/000164511323000039/nvcr-20230606.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001645113-23-000039
- JSON: https://secwatch.observer/filing/0001645113-23-000039.json
- Plain text: https://secwatch.observer/filing/0001645113-23-000039.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.